Thomas Franch
CHIEF SCIENTIFIC OFFICER
Biopharmaceuticals
Nuevolution
Denmark
Biography
Thomas Franch, Chief Scientific Officer holds an MSc and Ph.D in Molecular Biology from Odense University. During his education, he studied at the Institute of Biochemistry and Molecular Biology (BMB) at Odense University and at Uppsala University. Thomas joined Nuevolution in 2001, and has been a key scientist for the development and patent protection of the Chemetics® technology serving as project manager on several of the early technology development projects. From 2006, he served both as Chief Technology Officer and Director of Biology leading the company’s biology function and technological efforts including process optimization. Thomas was appointed Chief Scientific Officer in 2012. He has strong competences in Partnership Governance, Lead Discovery, Technology Development and significant experience in the fields of gene regulation, nucleic acid structure, function and biological stability, as well as antisense technology. Prior to joining Nuevolution, Thomas was the CEO of RNA Tech Aps enabling kinetic and efficacy improvements to antisense cancer therapeutics. Thomas Franch has authored or co-authored more than 40 publications and patent applications.
Research Interest
Focusing on delivering breakthrough medicines for treatment of cancer and inflammatory diseases
